Tag: Illumina

The prolonged regulatory battle has reached a critical resolution point, with Illumina commencing its mandated divestiture from GRAIL. This strategic ...

A significant trade barrier has been partially dismantled for genomics leader Illumina. After months of restricted access, Chinese authorities have ...

A significant regulatory shift from China has injected fresh momentum into Illumina's stock, as the country removes its export prohibition ...

Illumina has delivered a stunning quarterly performance that has reignited investor confidence in the genomics sector. The sequencing technology company, ...

The genomics sector is witnessing a tale of two narratives unfold at Illumina, where groundbreaking artificial intelligence initiatives are being ...

Biotechnology leader Illumina is renewing its growth strategy with an intensified focus on clinical diagnostics. The company aims to solidify ...

As its share price continues to struggle, Illumina is making a decisive strategic move by entering the human protein measurement ...

Genomics leader Illumina finds itself navigating a complex strategic landscape. The company's latest quarterly results reveal continued revenue pressure, even ...